Microparticle

ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma

Retrieved on: 
화요일, 5월 30, 2023
Investigational device exemption, Hepatocellular carcinoma, ABK, Research, Radiation therapy, MD, Patient, NS, Principal, IDE, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Microparticle, HCC, Food, Safety, Medical device, Medical imaging

The pivotal clinical study, Route90, is designed to evaluate the safety and efficacy of Eye90 microspheres in patients living with unresectable Hepatocellular Carcinoma (HCC).

Key Points: 
  • The pivotal clinical study, Route90, is designed to evaluate the safety and efficacy of Eye90 microspheres in patients living with unresectable Hepatocellular Carcinoma (HCC).
  • The Route90 study will evaluate HCC tumors' response rates and duration of response from Eye90 microspheres treatment as co-primary endpoints.
  • "We're motivated to begin this pivotal study and assess the Eye90 microspheres technology in a large well-controlled, well-designed study.
  • Mike Mangano, President, and CEO, ABK Biomedical , said: "FDA approval of this pivotal study is a significant milestone for ABK.

Global Embolotherapy Market Analysis/Forecasts, 2022-2023 & 2029 - Growing Patient Population With Chronic Conditions Increasing the Demand for Embolization Procedures - ResearchAndMarkets.com

Retrieved on: 
수요일, 2월 1, 2023
Health, Other Health, Hospital, Moyamoya disease, TACE, Urology, Microparticle, PVA, Transcatheter arterial chemoembolization, Neurology, TAE, Gelatin, Liver cancer, Arteriovenous malformation, Brachytherapy, Growth, Lung cancer, SIRT, Prevalence, Intracranial aneurysm, AVM, Video game, Speciality chemicals, Pharmaceutical industry, Nursing, Selective internal radiation therapy

The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029.

Key Points: 
  • The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029.
  • The liquid embolization agents market is expected to grow at early teens CAGR from 2022 to 2029.
  • Factors such as the growing patient population with chronic conditions increasing the demand for embolization procedures, and technology advancements are driving the market growth, whereas, acquisitions and collaborations and emerging markets are providing growth opportunities.
  • The Embolotherapy global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares.

Guerbet: 2023 Strategic Priorities

Retrieved on: 
월요일, 1월 16, 2023
Prostate cancer, European Medicines Agency, Algorithm, Face, HSG, Hysterosalpingography, Liver, X-ray, Environment, Watson (computer), Microparticle, Research, Google Images, Lymphogram, IBM Watson Health, Intellectual property, Iodine, Growth, Lipiodol, Intelligence, Liver cancer, MRI, Investment, Acquisition, EMA, Risk management, Medical imaging, Guerbet, Mer (software distribution)

Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

Key Points: 
  • Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.
  • In Europe, the European Medicines Agency (EMA) review is expected in the second half of the year.
  • Guerbet also plans to divest the Occlugel technology acquired in 2018, including several ranges of microspheres for use in embolization.
  • Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.

Polysciences Announces New Bioprocessing Brand, Kyfora Bio

Retrieved on: 
월요일, 1월 2, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Research, Microparticle, QA/QC, Polymer, QC, Quality management system, Laboratory, IVD, CDMO, D, CGMP, Lipid, R, Fine chemical

Polysciences, Inc., a Pennsylvania-based manufacturer of specialty chemicals for research, IVD and medical device applications, has announced its plan to create a new brand, Kyfora Bio, representing its product offerings to the bioprocessing market.

Key Points: 
  • Polysciences, Inc., a Pennsylvania-based manufacturer of specialty chemicals for research, IVD and medical device applications, has announced its plan to create a new brand, Kyfora Bio, representing its product offerings to the bioprocessing market.
  • Building on Polysciences’ extensive experience in developing and manufacturing monomers, polymers, microspheres, and specialty reagents for the medical device, diagnostic, and pharmaceutical industries, Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
  • Based in Horsham, PA, Kyfora Bio will occupy a 45,000 square foot cGMP facility outfitted with administrative offices, R&D laboratories, manufacturing suites, and QC laboratories for chemical and biological performance testing.
  • “Kyfora Bio reflects Polysciences’ latest commitment to be the partner of choice in supplying key cGMP compliant materials to the cell and gene therapy market.

Polysciences Announces New Bioprocessing Brand, Kyfora Bio

Retrieved on: 
월요일, 1월 2, 2023
Polymer, CDMO, Laboratory, Microparticle, D, R, IVD, Research, Multimedia, Quality management system, QA/QC, CGMP, QC, Lipid, Fine chemical, Online shopping

WARRINGTON, Pa., Jan. 2, 2023 /PRNewswire/ -- Polysciences, Inc., a Pennsylvania-based manufacturer of specialty chemicals for research, IVD and medical device applications, has announced its plan to create a new brand, Kyfora Bio, representing its product offerings to the bioprocessing market.

Key Points: 
  • WARRINGTON, Pa., Jan. 2, 2023 /PRNewswire/ -- Polysciences, Inc., a Pennsylvania-based manufacturer of specialty chemicals for research, IVD and medical device applications, has announced its plan to create a new brand, Kyfora Bio, representing its product offerings to the bioprocessing market.
  • Building on Polysciences' extensive experience in developing and manufacturing monomers, polymers, microspheres, and specialty reagents for the medical device, diagnostic, and pharmaceutical industries, Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
  • Based in Horsham, PA, Kyfora Bio will occupy a 45,000 square foot cGMP facility outfitted with administrative offices, R&D laboratories, manufacturing suites, and QC laboratories for chemical and biological performance testing.
  • "Kyfora Bio reflects Polysciences' latest commitment to be the partner of choice in supplying key cGMP compliant materials to the cell and gene therapy market.

ABK Biomedical Raises USD 30M in Series C Financing

Retrieved on: 
화요일, 12월 6, 2022
Ketan, Capital, Biomedicine, Physician, NS, R, Medtech, Partnership, Patient, Eight Roads Ventures, Research, GMP, Microparticle, FDA, Trial of the century, Multimedia, Liver cancer, ABK, Interventional oncology, Medical device

HALIFAX, NS, Dec. 6, 2022 /PRNewswire/ - ABK Biomedical, Inc. , an innovative medical device company dedicated to the research, development, and commercialization of advanced imageableembolic therapies, today announced an oversubscribed USD 30 million Series C financing.

Key Points: 
  • HALIFAX, NS, Dec. 6, 2022 /PRNewswire/ - ABK Biomedical, Inc. , an innovative medical device company dedicated to the research, development, and commercialization of advanced imageableembolic therapies, today announced an oversubscribed USD 30 million Series C financing.
  • The round is co-led by new investors Sant Ventures and a significant, undisclosed MedTech strategic investor.
  • ABKBiomedicalwilldirect thefundingtoseek FDA IDE approval to execute their Eye90 microspheres Route90 US pivotal trial and continue their clinical development programs.
  • "We have made tremendous progress at ABK over the past three years," said Mike Mangano, President and CEO of ABK Biomedical.

Global Vaccine Delivery Devices Market Report 2022: Technological Advancements in the Systematic Delivery of Vaccines to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
화요일, 10월 4, 2022
Pharmaceutical, Health, Medical Devices, Vaccine, Non-governmental organization, Toxicity, Anthrax Vaccine Immunization Program, Vaccine-preventable diseases, Disability, Coronavirus, Disease, Research, Prevalence, CAGR, Antibody, COVID-19, Infection, Immune system, Dendrimer, Microparticle, Electroporation, Death, USERN Prize, Investment, Liposome, Antigen, Nanoparticle, Pharmaceutical industry, Growth

The "Vaccine Delivery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vaccine Delivery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global vaccine delivery devices market reached a value of US$ 6.44 Billion in 2021.
  • Vaccine Delivery Devices Market Trends:
    Technological advancements in the systematic delivery of vaccines, such as micro-needles and electroporation, represent one of the key factors driving the market.
  • This, along with the rising research in the field of vaccines and the development of new vaccine delivery devices around the world, is propelling the growth of the market.

Bruce Power to explore production of cancer-fighting medical isotope yttrium-90 for global distribution

Retrieved on: 
월요일, 10월 3, 2022
YouTube, Y-90, Cancer, Saugeen Ojibway Nation Territory, Liver cancer, Medicine, IPS, Society, Saugeen First Nation, LinkedIn, Business development, Ojibwe, Twitter, Interventional oncology, Instagram, Boston Scientific, MOU, Partnership, TheraSphere, SON, TC Energy, Leadership, Electricity, Environment, Microparticle, Patient, Power, Bruce Power, OMERS, GLOBE, Medical imaging, Lithium, Facebook, Isotope, Isogenic human disease models

Medical isotopes save lives and Ontario is primed to become an isotope superpower, said Ontarios Energy Minister Todd Smith.

Key Points: 
  • Medical isotopes save lives and Ontario is primed to become an isotope superpower, said Ontarios Energy Minister Todd Smith.
  • Additionally, Bruce Power will soon become the first nuclear power reactor operator to commercially produce lutetium-177 through an innovative Isotope Production System (IPS).
  • The IPS is a first-of-its-kind solution to produce short-lived medical isotopes in a commercial reactor and will provide unprecedented capacity, redundancy and scale for medical isotope production.
  • Isogen will also work with Bruce Power and Boston Scientific on the feasibility of yttrium-90 production using the IPS.

Phosphorex Appoints Jarlath Keating as Chief Executive Officer

Retrieved on: 
월요일, 9월 19, 2022
GE, CGMP, Thermo Fisher Scientific, Knowledge, Organization, Growth, Merck Millipore, Industry, Patient, Ministry of Education (Malaysia), CEO, CDMO, Solution, Microparticle, Nanoparticle, Fine chemical, Ampersand, Jarlath

HOPKINTON, Mass., Sept. 19, 2022 /PRNewswire/ -- Followingthe recent growth capital investment from Ampersand Capital Partners,Phosphorex, a drug delivery-focused contract development and manufacturing organization ("CDMO") providing microspheres and polymer / lipid nanoparticles, announced today the appointment of Jarlath Keating as Chief Executive Officer.

Key Points: 
  • HOPKINTON, Mass., Sept. 19, 2022 /PRNewswire/ -- Followingthe recent growth capital investment from Ampersand Capital Partners,Phosphorex, a drug delivery-focused contract development and manufacturing organization ("CDMO") providing microspheres and polymer / lipid nanoparticles, announced today the appointment of Jarlath Keating as Chief Executive Officer.
  • Prior to Advanced Bioscience Laboratories, Jarlath held various senior commercial roles at MilliporeSigma, leading the global BioReliance commercial operations function.
  • Jarlath also held commercial and technical roles at industry leading organizations such as Thermo Fisher, GE and Lonza Biologics.
  • Bin Wu, Ph.D., Founder of Phosphorex, will assume the newly created role of President and Chief Scientific Officer.

ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

Retrieved on: 
월요일, 9월 12, 2022
Glass, Pectus carinatum, Vein, ABK, MD, FDA, Unified school district, Neoplasm, NOT, Program, Patient, HCC, Physician, Technology, Pain, Blood, Arteriovenous malformation, Microparticle, Research, Capillary, Multimedia, Artery, Medical device, Medical imaging, NS

HALIFAX, NS, Sept. 12, 2022 /PRNewswire/ - ABK Biomedical, Inc. , an innovative medical device company dedicated to the research, development, and commercialization of advanced imageableembolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors.

Key Points: 
  • HALIFAX, NS, Sept. 12, 2022 /PRNewswire/ - ABK Biomedical, Inc. , an innovative medical device company dedicated to the research, development, and commercialization of advanced imageableembolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors.
  • Vascular embolization, performed by interventional radiologists, is an effective therapy for addressing the symptoms of patients suffering from this condition.
  • Hypervascular tumors occur in both benign and malignant states and are characterized by blood supply from an abnormally large number of blood vessels.
  • Microspheres embolization reduces or eliminates the blood flow to these tumors and is an effective interventional radiology therapy for treating this disease state.